Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA   US04033A1007

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/11/2014 12/12/2014 12/15/2014 12/16/2014 12/17/2014 Date
6.475(c) 6.34(c) 6.1(c) 6.08(c) 6.36(c) Last
13 659 534 4 903 559 5 485 135 5 469 691 5 258 505 Volume
-7.76% -2.08% -3.79% -0.33% +4.61% Change
More quotes
Company
ARIAD Pharmaceuticals, Inc. operates as a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer.The company has four products: Ridaforolimus, Ponatinib, AP1903 and AP26113.Its approach to structure-based drug... 
Sector
Pharmaceuticals
Calendar
02/24Earnings Release
More about the company
Surperformance© ratings of Ariad Pharmaceuticals, Inc
Trading Rating : Investor Rating :
More Ratings
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 64,5 M
EBIT 2014 -203 M
Net income 2014 -211 M
Finance 2014 78,2 M
Yield 2014 -
Sales 2015 159 M
EBIT 2015 -136 M
Net income 2015 -135 M
Finance 2015 31,2 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 17,2x
EV / Sales 2015 7,31x
Capitalization 1 191 M
More Financials
Latest news on ARIAD PHARMACEUTICALS, INC
1m ago ARIAD PHARMACEUTICALS : Announces Follow-up Data from Phase 1 and PACE Trials of..
1d ago ARIAD PHARMACEUTICALS : Announces Long-Term Safety and Efficacy Data of Ponatini..
1d ago ARIAD PHARMACEUTICALS : Announces Long-Term Safety and Efficacy Data of Ponatini..
7d ago ARIAD PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form 8-..
12/09 ARIAD PHARMACEUTICALS : Announces Follow-up Data from Phase 1 and PACE Trials of..
12/09 ARIAD PHARMACEUTICALS : Announces Long-Term Safety and Efficacy Data of Ponatini..
12/08 ARIAD PHARMACEUTICALS : Announces Long-Term Safety and Efficacy Data of Ponatini..
12/06 ARIAD PHARMACEUTICALS : Iclusig (Ponatinib) Gets Approval in Australia
More news
Sector news
7m ago ASTRAZENECA : Gets Marketing Approval For Lynparza Cancer Treatment
7m ago ASTRAZENECA : Lynparza™approved in the European Union as first-in-class tr..
13m ago KYOWA HAKKO KIRIN : Approval for Additional Indication for Chemotherapy-Native C..
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF